CONCORD
Concord Drugs financials
- Market cap
- ₹107 Cr
Quarterly results
Q1 FY27: revenue up 53.9%, net profit up 825.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 11 | 10 | 14 | 10 −17% | 17 +57% | 38 +265% | 21 +54% |
| EBITDA | 1 | 1 | 1 | 1 | 1 +25% | 1 −33% | 2 +43% | 2 +125% |
| Net profit | 0 | 0 | 0 | 0 | 0 +375% | 0 −4% | 1 +1225% | 1 +825% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +16.1% 1Y
1Y: ₹68.66 on 10 Sept 2025 → ₹79.68. High ₹90.08 (7 Jan 2026), low ₹61.98 (21 Oct 2025).
Financials, as filed
Revenue grew 32.4% a year over 2 years, FY24 to FY26. Operating margin narrowed to 5.8%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹45 Cr | ₹45 Cr | ₹79 Cr |
| Operating profit | ₹4 Cr | ₹4 Cr | ₹5 Cr |
| Operating margin | 9.0% | 9.2% | 5.8% |
| Interest | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Depreciation | ₹2 Cr | ₹1 Cr | ₹1 Cr |
| Net profit | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Net margin | 1.0% | 0.8% | 1.3% |
| Cash from operations | ₹1 Cr | ₹4 Cr | ₹-7 Cr |
| Free cash flow | ₹-0 Cr | ₹1 Cr | ₹-8 Cr |
| ROCE | 5.0% | 5.2% | 5.5% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity capital | ₹9 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr | ₹13 Cr |
| Reserves | ₹20 Cr | ₹22 Cr | ₹24 Cr | ₹24 Cr | ₹35 Cr |
| Borrowings | ₹16 Cr | ₹17 Cr | ₹18 Cr | ₹17 Cr | ₹14 Cr |
| Other liabilities | ₹12 Cr | ₹10 Cr | ₹7 Cr | ₹17 Cr | ₹13 Cr |
| Total liabilities | ₹56 Cr | ₹58 Cr | ₹59 Cr | ₹69 Cr | ₹75 Cr |
| Fixed assets | ₹14 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
| Capital work in progress | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Investments | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Other assets | ₹42 Cr | ₹44 Cr | ₹45 Cr | ₹54 Cr | ₹60 Cr |
| Total assets | ₹56 Cr | ₹58 Cr | ₹59 Cr | ₹69 Cr | ₹75 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −9.31 pp while the public added +9.31 pp. The shareholder count shrank 15% to 4,435.
- Promoters
- 45.1%
- Public
- 54.9%
Since Jun 2025
- Promoters −9.31 pp
- Public +9.31 pp
How it drifted, 12 quarters
Over this window promoters fell from 52.1% to 45.1% — −7.0 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 52.1%, Public 47.9%.Dec '23: Promoters 55.4%, Public 44.6%.Mar '24: Promoters 55.4%, Public 44.6%.Jun '24: Promoters 55.4%, Public 44.6%.Sep '24: Promoters 54.4%, Public 45.6%.Dec '24: Promoters 54.4%, Public 45.6%.Mar '25: Promoters 54.4%, Public 45.6%.Jun '25: Promoters 54.4%, Public 45.6%.Sep '25: Promoters 54.4%, Public 45.6%.Dec '25: Promoters 54.4%, Public 45.6%.Mar '26: Promoters 54.4%, Public 45.6%.Jun '26: Promoters 45.1%, Public 54.9%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- C Sushmitha newly disclosed 8.35% held
- Pranali Bangad newly disclosed 2.28% held
- Anjana Bangad newly disclosed 2.28% held
- Anuradha Bangad newly disclosed 2.28% held
- Vikas Bangad newly disclosed 2.28% held
- Komal Sharma newly disclosed 1.57% held
- Mohan Thodupunuri +0.14 pp 1.15% held
The same filing shows 5 holders trimming and 5 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Concord Drugs Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Nagi Reddy Seelam | 23.23% | −5.38 pp |
| Manojkumarreddy Seelam | 13.50% | −2.78 pp |
| Seelam Koni Reddy | 8.35% | −1.16 pp |
| C Sushmitha | 8.35% | newly disclosed |
| Pranali Bangad | 2.28% | newly disclosed |
| Anjana Bangad | 2.28% | newly disclosed |
| Anuradha Bangad | 2.28% | newly disclosed |
| Vikas Bangad | 2.28% | newly disclosed |
| Komal Sharma | 1.57% | newly disclosed |
| Ganga Devi Loya | 1.48% | −0.46 pp |
| Mohan Thodupunuri | 1.15% | +0.14 pp |
| Rajendra Kumar Agarwal | 1.13% | −0.36 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Concord Drugs Limited
Guides on how to read this kind of business and the numbers that matter.